The commitment entails a subscription of approximately USD 9.6 million through exercise of purchased subscription rights and a subscription of approximately USD 0.4 million without the use of subscription rights.

“We are delighted to welcome Sanofi, one of the world’s leading biopharmaceutical companies, as an investor in Vicore as we initiate late-stage development of buloxibutid,” says Ahmed Mousa, Chief Executive Officer of Vicore. “This investment supports our belief in the potential of buloxibutid as a transformative therapy for patients suffering from IPF.”

As any allocation to the investors who entered into guarantee commitments shall only be made up to the number of shares corresponding to the committed amount before the announcement of the rights issue, this additional subscription undertaking does not entail an increase in the percentage to which the rights issue is covered by subscription undertakings, subscription intentions and guarantee commitments.